The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

VOLUNTARY ANNOUNCEMENT SIGNING OF AI HEALTHCARE STRATEGIC COOPERATION AGREEMENT

This announcement is made by Tianjin TEDA Biomedical Engineering Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of providing shareholders and potential investors of the Company the latest information regarding the business development of the Group.

SIGNING OF AI HEALTHCARE STRATEGIC COOPERATION AGREEMENT

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that Shanghai Suihong Huachuang Technology Co., Ltd.*(上海燧弘華創科技有限公司)("**Suihong Huachuang**"), a subsidiary of Xiamen Hongxin Electronics Technology Group Inc. (stock code: 300657, a listed company on the A-share market), entered into an AI healthcare strategic cooperation agreement (the "**Cooperation Agreement**") with the Company recently. Both parties will give full play to their respective advantages in resources, talents and technologies to establish long-term strategic cooperation centered around the professional operations and marketing of AI healthcare and data business, the construction of intelligent computing centers and the provision of computing power in the healthcare field, and the overall solutions and ancillary support of diversified heterogeneous computing power hardware.

REASONS FOR AND BENEFITS OF SIGNING THE STRATEGIC COOPERATION AGREEMENT

The Group is currently fully committed to advancing the research and development, and the commercialization of its AI medical large model business and related data business. Among which, high-quality computing power resources, stable hardware solutions, and extensive marketing channels are critical elements supporting the efficient development of these businesses. To ensure persistent and steady progress of its business, the Company will actively engage in resources matching and partnership discussions around these key areas, laying a solid foundation for its long-term business development.

The Board believes that the signing of the strategic cooperation agreement with Suihong Huachuang can achieve complementary advantages in resources and technology for both parties: firstly, it can provide direct and strong marketing support for the Company's AI medical large models and related data business by leveraging government partnerships and matured sales channels acquired by Suihong Huachuang from the construction of intelligent computing centers and the production and manufacturing business of computing power servers that enables the Company to quickly reach its target markets; secondly, by utilizing Suihong Huachuang's core technical capabilities in the fields of AI computing power infrastructure construction, intelligent computing center operations, as well as hardware production and manufacturing, it can provide stable and efficient computing power guarantee and cost-effective hardware supporting solutions for trainings optimization and actual application scenarios implementation of the AI medical large models of the Company, which can effectively reduce our business promotion costs, thereby accelerating the transformation and implementation of the Company's relevant technological achievements into commercial applications.

COOPERATION AGREEMENT

Both parties will fully leverage their respective resources, talents and technological advantages to establish long-term strategic cooperation centered around the construction of intelligent computing centers and computing power provision in the healthcare field, ancillary support for diversified heterogeneous computing power hardware solutions including Suihong Huachuang's all-in-one medical devices, marketing promotion of AI healthcare applications and data business, professional operations, and channel development, etc., in order to achieve mutual development for both parties in the field of AI healthcare applications and data business.

The main contents of the cooperation include:

1. Computing power resources and infrastructure coordination: Suihong Huachuang will provide the Company with high-quality computing power resources based on the intelligent computing centers constructed and operated by itself, at a price not higher than the market level of its peers to meet the subsequent computing power needs for AI healthcare and data business of the Company. At the same time, the Company will prioritize the utilization of Suihong Huachuang's computing power resources services. Suihong Huachuang will provide the Company with computing power resources at a price not higher than the market level of its peers, and the Company will assist Suihong Huachuang in expanding intelligent computing centers in areas where the Company has advantageous resources.

2. Hardware technology and product collaboration: The Company will prioritize the adoption of computing power hardware and solutions from Suihong Huachuang, provided that the requirements of technical parameters are met and the price is favorable, and will entrust Suihong Huachuang to produce AI healthcare all-in-one medical devices; both parties will be committed to jointly promoting the applications of the NVIDIA ecosystem, domestic ecosystems, and Suihong Huachuang's all-in-one medical devices in the AI healthcare field. They have jointly formed a research and development team and other technical collaboration mechanisms in the development of AI all-in-one healthcare medical devices. At the same time, Suihong Huachuang has committed to provide the Company with a certain discount on price for hardware purchases.

3. Application scenarios implementation and ecosystem co-construction: Both parties will together facilitate the application scenarios implementation and marketing of AI healthcare and data business. They have established an AI medical joint innovation center in Haicang District, Xiamen, to introduce more resource partners for implementing applications and jointly build an AI+ healthcare ecosystem demonstration base.

4. Market and channel resources sharing: Both parties will share their respective industry resources, including government partnerships and medical institution channels, to enhance market penetration in areas such as marketing and channel development. Specifically, Suihong Huachuang will provide its channel resources of local government computing power infrastructure construction (including but not limited to manufacturing bases and intelligent computing centers) and prioritize product sales of the Company in Haicang District, Xiamen; the Company will prioritize the utilization of Suihong Huachuang's computing power hardware and solutions provided in its own AI healthcare models.

5. Joint ventures to jointly expand business: Both parties intend to agree to contribute in cash and jointly establish an AI computing power resources services joint venture and an AI medical applications joint venture in Haicang District, Xiamen City.

   Suihong Huachuang will hold 80% and the Company will hold 20% of the AI computing power resources services joint venture respectively. The AI computing power resources services joint venture will build and operate edge and device computing power infrastructure, so as to provide computing power resources services to the Company and its cooperative partners in the AI medical large model and data business ecosystem.

   The Company will hold 51% and Suihong Huachuang will hold 49% of the AI medical applications joint venture respectively. The AI medical applications joint venture will engage in (including but not limited to) the following two businesses: 1. Incubate healthcare aspect (medical institutions) of AI medical application scenarios models and promote the applications of all-in-one medical devices (including but not limited to integrated medical diagnosis and treatment devices and wearable medical devices). This will empower medical institutions and physicians through leading products such as healthcare and management-guided pre-diagnosis large models, remote intelligent screening models for congenital heart disease of newborns, the "Xihe No. 1" pre-diagnosis and triage all-in-one medical devices, and pediatric epilepsy diagnosis systems. On the one hand, such joint venture will generate one-time revenue from the sales of all-in-one medical devices and on the other hand, it will also generate ongoing subscription fees from the usage of healthcare-based large models to promote industry collaboration; 2. Leveraging the advantages on data resources of Suihong Huachuang and the advantages on data governance, database systems, and data analytics of the Company, such joint venture will provide full-stack management of data and analytics solutions to clients in healthcare, government affairs, finance, and manufacturing fields, supporting corporate digital transformation and upgrade.

INFORMATION ON SUIHONG HUACHUANG

Suihong Huachuang is a powerful and leading technology company in AI computing power infrastructure construction. It has a fully integrated and low-cost production and manufacturing base for domestically produced, high-performance AI computing power servers and operates green intelligent computing centers in various locations. With its hardware business expertise in computing power servers and intelligent computing center infrastructure, Suihong Huachuang is actively expanding into AI healthcare and data business field, demonstrating its strong capabilities in technology integration, industry chain collaboration, and application scenarios implementation.

INFORMATION ON THE GROUP

The Group is fully committed to promoting the research and development and the commercialization of its AI medical large model business and related data business. The Group has introduced an internationally leading healthcare software platform covering various niche application scenarios such as biopharmaceuticals, digital healthcare, medical devices, medical imaging, and genomics, which can provide significant AI solutions support in the healthcare and life science fields. Based on the closed-source data derived from millions of real medical records from Peking University Third Hospital, a top-tier tertiary hospital, the Group has already developed the "Xihe No. 1" medical large model, a Chinese-English bilingual model driven by pathology rather than data fitting with hundreds of billions of parameters powered by the dual engines of natural language interaction and traceable knowledge reasoning. Capitalized on the educational and medical resources of Peking University, the Group has jointly established a healthcare intelligence computing laboratory with the School of Software and Microelectronics of Peking University, focusing on AI healthcare applications research and development as well as its marketing; as an officially approved core ecological partner of Shenzhen Institute of Computing Sciences, the Group is deeply engaged in the integration of database systems, data governance and data analytics technologies with industry application scenarios, and can provide full stack management of data and intelligent analytics solutions for clients in healthcare, government affairs, finance and manufacturing fields.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
27 August 2025

As at the date of this announcement, the executive Director of the Company is Ms. Sun Li; the non-executive Directors of the Company are Mr. He Xin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive Directors of the Company are Mr. Wang Yongkang, Ms. Gao Chun and Mr. Tu Xiangzhen.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the "Latest Company Information" page for seven days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.

* *For identification purposes only*